CD22 antibody (PE)

Catalog No. ABIN1112094

Product Details anti-CD22 Antibody (PE)

Target: CD22 (CD22 Molecule (CD22))

Reactivity: Human

Host: Please inquire

Clonality: Monoclonal

Conjugate: This CD22 antibody is conjugated to PE

Application: Flow Cytometry (FACS), Immunofluorescence (IF)

Characteristics: CD22 PE MoAb is recommended for use in flow cytometry for identification of B cells subsets, so much mature as late pro- and early pre-B cells..

Clone: HIB22

Isotype: IgG1

Application Details

Application Notes: It is recommended for use in flow cytometry. This reagent is effective for direct immunofluorescence staining of human tissue for flow cytometric analysis using 20 µl/10^6 cells.

Comment:

R-Phycoerythrin (Europa Bioproducts, Ely, Cambridge).

Sample Collection: 1. Transfer 100 µl of anticoagulated (EDTA) blood to a 12 x 75 mm polystyrene test tube (10^6 cells). 2. Add 20 µl of CD22 PE and mix gently with a vortex mixer. The 20 µl is a guideline only, the optimal volume should be determined by the individual laboratory. 3. The recommended negative control is a non-reactive PE-conjugated antibody of the same isotype. 4. Incubate in the dark at room temperature at 4°C for 30 minutes or at room temperature (20-25 °C) for 15 minutes. 5. Add 1,5 ml of Lysing Solution to each sample and mix gently with a vortex mixer. Incubate for 10 minutes at room temperature in the dark. 6. Centrifuge at 1000 x g for 5 minutes. Gently aspirate the supernatant and discard it leaving approximately 50 µl of fluid. 7. Add 2 ml 0.01 mol/l PBS (It betters that it containing 2% bovine serum albumin) and resuspend the cells by using a vortex mixer. 8. Centrifuge at 1000 x g for 5 minutes. Gently aspirate the supernatant and discard it leaving approximately 50 µl of fluid. 9. Resuspend pellet in an appropriate fluid for flow cytometry, e.g. 0.3 ml PBS. The PBS should contain 1% paraformaldehyde (fixative) if samples are not analysed the same day. 10. Analyse on a flow cytometer or store at 2-8 °C in the dark until analysis. Samples can be run up to 24 hours after lysis.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: The conjugate is provided in liquid form in buffer containing 1% bovine serum albumin (BSA) and 0,09% Sodium azide, pH 7.2.

Preservative: Sodium azide

Precaution of Use: 1. The device is not intended for clinical use including diagnosis, prognosis, and monitoring of a disease state, and it must not be used in conjunction with patient records or treatment. 2. This product contains Sodium azide (NaN3), a chemical highly toxic in pure form. At product concentrations, though not classified as hazardous, Sodium azide may react with lead and copper plumbing to form highly explosive build-ups of metal azides. Upon disposal, flush with large volumes of water to prevent metal azide build-up in plumbing. 3. As with any product derived from biological sources, proper handling procedures should be used.

Storage: 4 °C

Target Details for CD22

Target: CD22 (CD22 Molecule (CD22))

Alternative Name: CD22 (CD22 Products)

Synonyms: A530093D23 antibody, Lyb-8 antibody, Lyb8 antibody, SIGLEC-2 antibody, SIGLEC2 antibody, siglec-2 antibody, CD22 antigen antibody, CD22 molecule antibody, Cd22 antibody, CD22 antibody

Background: Heterodimer composed of two glycoprotein chains of 130 - 140 kDa molecular weight glycoprotein chains The antigen is present as both a cytoplasmic and membrane antigen on B lymphocytes. The CD22 antigen is expressed in the cytoplasm of the majority of B lymphocytes including early B progenitor cells. Antigen expression appears at an early stage in B lymphocyte differentiation at approximately the same stage as the CD19 antigen. Surface expression of the CD22 antigen by B lymphocytes is variable. Circulating B lymphocytes are CD22+ and follicular mantle and marginal zone B lymphocytes show strong binding of CBL147. Germinal centre B cells exhibit only weak expression of the CD22 antigen. The CD22 antigen is poorly expressed by non-T ALL cells and by a proportion of B- CLL cells. Hairy cell leukeamia cells have been demonstrated to strongly express the CD22 antigen.